SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The proportion of patients affected by a fibrotic form of liver disease according to NAFLD fibrosis score, and FIB-4, reduced significantly after 6 months of therapy in the SGLT2 inhibitors group, the main difference with the current study is the fact that they enrolled only patients with fibrosis.